Last reviewed · How we verify

NCT06734234

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

Recruiting now Phase 1 Last updated 7 August 2025
What this trial tests

Phase 1 trial testing GSK4771261 in Kidney Disease in 84 participants. Currently enrolling.

Timeline
11 December 2024
Primary endpoint
4 September 2026
4 September 2026

Quick facts

Lead sponsorGlaxoSmithKline
PhasePhase 1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingtriple
Primary purposetreatment
Enrollment84
Start date11 December 2024
Primary completion4 September 2026
Estimated completion4 September 2026
Sites14 locations across France, Belgium, United Kingdom, Germany, Canada, Spain

Drugs / interventions tested

Conditions studied

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 25 to 65, any sex, with Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study where a new drug, called GSK4771261 is being tested. Neither the study doctors, study staff or participants will be aware of what treatment is being given. Part A is testing the new study treatment on healthy people. This is to see if it's safe, what it does to the body, and how the body's defense system responds to it. Part B is similar, but the study treatment will be given to people who have a kidney disease called autosomal dominant polycystic kidney disease (ADPKD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Kidney Disease

Currently open trials in the same condition.

Other GlaxoSmithKline trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06734234.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing